Trial · NCT01408732
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
NCT01408732, Phase 1, Phase 2, Completed, University of Minnesota; results first posted 2018-04-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia. Trials, record NCT01408732. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01408732
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
- NCT number
- NCT01408732
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- University of Minnesota
- Conditions
- Epistaxis, Hereditary Hemorrhagic Telangiectasia
- Interventions
- Sclerotherapy, Standard Treatment
- First posted
- 2011-08-03
- Last updated
- 2019-11-01
- Results first posted
- 2018-04-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Severityof Epistaxis | Change from Baseline to 14 weeks | The primary outcome measure will be severity of epistaxis as measured by the Epistaxis Severity Score (ESS). The ESS, a recently developed online questionarrie that calculates the grading system for epistaxis severity. The higher the score the more severe the nose bleeds are Scale consists of several questions with a range of scale from 0-5 The average score is calculated for a final assessment |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Severityof Epistaxis | Change from Baseline to 14 weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Severityof Epistaxis | Sclerotherapy Intervention | -0.4578 | Standard Deviation 2.8943 | units on a scale | |
| Severityof Epistaxis | Standard Treatment | -1.4375 | Standard Deviation 4.1993 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sclerotherapy Intervention Then Standard Treatment | 9 | |
| Overall Study | STARTED | Standard Treatment Then Sclerotherapy | 9 | |
| Overall Study | COMPLETED | Sclerotherapy Intervention Then Standard Treatment | 7 | |
| Overall Study | COMPLETED | Standard Treatment Then Sclerotherapy | 7 | |
| Overall Study | NOT COMPLETED | Sclerotherapy Intervention Then Standard Treatment | 2 | |
| Overall Study | NOT COMPLETED | Standard Treatment Then Sclerotherapy | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sclerotherapy Intervention | ||
| Total, all-cause mortality | Standard Treatment | ||
| Total, other adverse events | Sclerotherapy Intervention | 0 | 18 |
| Total, other adverse events | Standard Treatment | 0 | 18 |
| Total, serious adverse events | Sclerotherapy Intervention | 0 | 18 |
| Total, serious adverse events | Standard Treatment | 0 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Sclerotherapy Intervention vs Standard Treatment: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01408732
GET https://conductscience.org/api/trials/v1/NCT01408732/registered